Bmab1700

Monoclonal antibody

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Featured evidence outside this drug's tracked markets:NCT07476326 · Melanoma · Phase 1 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity
NCT07476326 · Biocon Biologics UK PLC
2026-09-09 – 2028-02-16 · Melanoma
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 26 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bmab1700: this drugPhase 1Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
Cemiplimab
Approved(overall)
Monoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
Dostarlimab
Approved(overall)
Monoclonal antibodyPD-1Partial signal
NCT03602859: Progression Free Survival (PFS) (Up to approximately 316 weeks): Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) 19.19 Months (95% CI 16.59 to 20.99) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) 20.63 Months (95% CI 19.22 to 22.77)
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
Nivolumab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT03036098: Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results).
Opdivo Qvantig
Approved(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
Pembrolizumab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023).
NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)
Approved(overall)
Monoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only
Penpulimab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
Retifanlimab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
Tislelizumab
Approved(overall)
Monoclonal antibodyPD-1Partial signal
NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed
NCT03412773: Overall survival, tislelizumab vs sorafenib: median 15.9 vs 14.1 months, hazard ratio 0.85 (95.003% CI 0.712 to 1.019); upper bound below the 1.08 non-inferiority margin, so non-inferior; superiority not shown (one-sided p=0.0398 vs boundary 0.0223) (CT.gov posted results).
Toripalimab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT04085276: PFS in the intent-to-treat population (this trial's stated primary analysis population): median 8.4 vs 6.9 months, HR 0.77, P=0.0445, toripalimab+nab-paclitaxel vs placebo+nab-paclitaxel. Also reported for the PD-L1-positive population: median 8.4 vs 5.6 months, HR 0.653, 95% CI 0.470-0.906, P=0.0102
Abp 234
Phase 3(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
BAT3306
Phase 3(overall)
Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary
Camrelizumab
Phase 3(overall)
Monoclonal antibodyPD-1Partial signal
NCT04613674: Pathological complete response: 56.8% (126/222) camrelizumab+chemotherapy vs 44.7% (98/219) placebo+chemotherapy; rate difference 12.2% (95% CI 3.3%-21.2%), 1-sided P=.004
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
Cetrelimab
Phase 3(overall)
Monoclonal antibodyPD-1Weak signalFeatured results are safety only
CT-P51
Phase 3(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
Enlonstobart
Phase 3(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
MB12
Phase 3(overall)
Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary
Serplulimab
Phase 3(overall)
Monoclonal antibodyPD-1Reliable signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
Sintilimab
Phase 3(overall)
Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
Budigalimab
Phase 2/3(overall)
Monoclonal antibodyPD-1not yet graded
NCT03000257: Phase 1 dose-escalation confirmed tolerability and linear PK; RP2D established
Sasanlimab
Phase 2/3(overall)
Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only
Balstilimab
Phase 2(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
SHR-3045
Phase 2(overall)
UndisclosedPD-1not yet gradedNo reviewed efficacy summary
IOV-4001
Phase 1/2(overall)
Cell therapyPD-1not yet gradedNo reviewed efficacy summary
OSE-279
Phase 1/2(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bmab1700 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2027-08-16 · NCT07476326 · CT.gov ↗
What to watch

See the full readout calendar ↗